Actively Recruiting
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Led by Queen Mary University of London · Updated on 2026-01-07
40
Participants Needed
2
Research Sites
256 weeks
Total Duration
On this page
Sponsors
Q
Queen Mary University of London
Lead Sponsor
B
Biogen
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Disease Modifying Treatment (DMT) begins. Evidence suggests that shutting down inflammation using highly effective DMTs early after diagnosis leads to better long term clinical outcomes The AttackMS trial will test the effect of starting a highly-effective DMT licensed for MS, Tyruko® (Natalizumab 300mg), within a short time - 14 days - after symptom onset.
CONDITIONS
Official Title
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant has provided informed consent.
- Age 18-55 years.
- Participant with clinically isolated syndrome (CIS) or multiple sclerosis (MS) at first presentation.
- Participants show two or more lesions on T2 weighted MRI suggestive of demyelination.
- Participant is willing and able to comply with clinical visits and procedures outlined in the study protocol.
You will not qualify if you...
- Hypersensitivity to Tyruko4 or any excipients including histidine, histidine monohydrochloride, sodium chloride, polysorbate 80 (E433), or water for injections.
- Evidence of multiple chronic demyelinating lesions on MRI without recent activity.
- Increased risk for opportunistic infections or immunocompromised due to current or prior therapies.
- Use of other disease-modifying treatments.
- Known active malignancies except cutaneous basal cell carcinoma.
- Implants incompatible with MRI such as pacemaker, brain aneurysm clip, or prosthetic heart valves.
- Significant comorbidities including cardiac failure, renal failure, uncontrolled diabetes, or uncontrolled hypercholesterolemia.
- History of stroke, thrombosis, or myocardial infarction.
- Any other clinically significant infection.
- Claustrophobia.
- Pregnancy or breastfeeding.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Royal London Hospital
London, United Kingdom, E1 1FR
Not Yet Recruiting
2
St George's Hospital
London, United Kingdom, SW17 0QT
Actively Recruiting
Research Team
K
Klaus Schmierer
CONTACT
J
Julia Elizabeth Phillips
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here